ArticleOPEN ACCESS

Erratum: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer (PLoS ONE (2013) 8:3 (E54014) DOI: 10.1371/journal.pone.0054014)

PLoS ONE
DOI: 10.1371/journal.pone.0261994
0Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This article was republished on October 20, 2020, to remove a Supporting Information file that was incorrectly included in the originally published article. Please download this article again to view the correct version.

Cite

CITATION STYLE

APA

Shah, M. A., Wainberg, Z. A., Catenacci, D. V. T., Hochster, H. S., Ford, J., Kunz, P., … Bottaro, D. P. (2021, December 1). Erratum: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer (PLoS ONE (2013) 8:3 (E54014) DOI: 10.1371/journal.pone.0054014). PLoS ONE. Public Library of Science. https://doi.org/10.1371/journal.pone.0261994

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free